The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation
- PMID: 20395429
- PMCID: PMC2877822
- DOI: 10.2353/ajpath.2010.100200
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation
Abstract
This commentary discusses the non-immune effects of fingolimod on neuroimmunological diseases.
Comment on
-
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.Am J Pathol. 2010 Jun;176(6):2682-94. doi: 10.2353/ajpath.2010.091234. Epub 2010 Apr 22. Am J Pathol. 2010. PMID: 20413685 Free PMC article.
References
-
- Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, (FREEDOMS Study Group) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401. - PubMed
-
- Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, (TRANSFORMS Study Group) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–415. - PubMed
-
- Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8:1295–1301. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
